巴甲替尼在治疗肠道综合症中
一项多中心,前瞻性,开放标签,随机研究,探索Bariticinib在难治性肠道behçet综合征患者中的功效和安全性
This study aims to conduct a randomized controlled trial to compare the efficacy and safety of Baricitinib and Adalimumab (ADA) in the treatment of refractory intestinal Behçet's Syndrome (BS). The objective is to demonstrate if Baricitinib is non-inferior to ADA in controlling BS inflammation, reducing BS recurrence, alleviating gastrointestinal symptoms and promoting intestinal mucosal healing.
研究概览
详细说明
The non-inferiority will be established by comparing the lower bound of the two-sided 95% confidence interval with the non-inferiority margin. If the lower bound was larger than the margin, Baricitinib would be regarded as non-inferiror to ADA. Superority will be further assessed in case that the non-inferiority is established. Both ITT and PP analysis will be conducted for the primary outcome given the non-inferiority design. Trial result will be primarily interpreted based on ITT analysis.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Wenjie Zheng, M.D.
研究联系人备份
- 姓名:Jinjing Liu, M.D.
- 电话号码:86-10-69151188
- 邮箱:pumch_followup@126.com
学习地点
-
-
-
Beijing、中国
- 招聘中
- Peking Union Medical College Hospital
-
接触:
- Jinjing Liu
- 电话号码:86-10-69151188
- 邮箱:pumch_followup@126.com
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100730
- 尚未招聘
- Peking Union Medical College Hospital
-
接触:
- Wenjie Zheng, M.D.
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Refer to the consensus on the diagnosis and treatment of intestinal Behçet's syndrome in China: Patients who meet the 2013 International Criteria for Behçet's Disease (ICBD) and have typical Behçet's syndrome-related intestinal ulcers confirmed by colonoscopy, or patients diagnosed according to the criteria for Behçet's syndrome established by the Korean Behçet's Disease Collaborative Group in 2009;
- Patients have a DAIBD score ≥ 40 points or intestinal symptom score ≥ 3 points at baseline;
- Endoscopic examination conducted within 60 days before inclusion suggests active intestinal ulcers;
- Patients who have been treated with medium to high-dose steroids (prednisolone equivalent of 0.5-1 mg/kg/day) for more than 1 month continuously, or any immunomodulator/Immunosuppressants for more than 3 months regularly or biologics for more than 2 months, as judged by the doctor to be treatment failure or intolerance;
- Currently steroid dose ≤ 30 mg prednisolone equivalent, stabilized for ≥ 2 weeks, and/or stabilized immunomodulator dose for ≥ 4 weeks;
- Understanding the research process, voluntary participation, and signing of informed consent.
Exclusion Criteria:
- Diagnosis of other diseases such as Crohn's disease, ulcerative colitis, lymphoma, etc.;
- Other active organ damage related to BS requires intensified immunosuppressive therapy, including aneurysms, uveitis, and substantial involvement of the central nervous system; skin lesions and joint involvement can be included;
- Severe organ dysfunction including ALT, AST, TBIL levels exceeding twice the upper limit of normal, creatinine levels exceeding 1.5 times the upper limit of normal, white blood cell count < 3×10^9/L, ANC < 2×10^9/L, hemoglobin < 80g/L, platelets < 100×10^9/L;
- Active infections such as active tuberculosis, active hepatitis B or C, syphilis, chronic Epstein-Barr virus infection, HIV infection, sustained or severe bacterial or viral infections, and history of severe herpes zoster;
- Patients with latent tuberculosis must undergo ≥3 weeks of prophylactic anti-tuberculosis treatment before inclusion;
- Primary immunodeficiency disease;
- History of cancer, or endoscopic intestinal histopathology indicating intraepithelial neoplasia or malignancy, or presence of other malignancies;
- Patients who did not respond to infliximab treatment for primary refractory BS (patients with secondary failure, intolerance, or allergy to infliximab should be included);
- Patients treated with biologics/small molecule targeting therapies within 5 half-lives (including use of tofacitinib within 10 days, etanercept within 4 weeks, infliximab within 8 weeks, golimumab, certolizumab, abatacept, and tocilizumab within 10 weeks, ustekinumab within 6 months);
- Patients with prior use of baricitinib or ADA;
- Complications of intestinal BS such as symptomatic stenosis, short bowel syndrome, intestinal fistula, or suspected intra-abdominal abscess; potential need for surgery or situations not conducive to DAIBD and efficacy assessment; any form of intestinal resection or other abdominal surgery within 6 months before baseline; presence of a functioning (i.e., patent) stoma or ostomy;
- Patients requiring parenteral nutrition due to disease severity;
- Pregnant, lactating, or planning pregnancy soon;
- Patients unwilling or unable to comply with regular visits;
- History of severe thrombotic events or chronic cardiovascular events.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Bariticinib用于IBS
|
Participants randomized to this arm will maintain their original steroids and/or immunomodulators, combined with Baricitinib 4 mg/day for 6 months.
其他名称:
|
|
实验性的:IBS的Adalimumab
|
Participants randomized to this arm will maintain their original steroids and/or immunomodulators, combined with ADA (initially ADA 160 mg subcutaneous injection, followed by 80 mg ADA after 2 weeks, then 40 mg ADA every 2 weeks thereafter) for 6 months.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of patients with marked improvement (MI) at week 24 of follow-up
大体时间:Baseline to week 24
|
Based on the combined assessment of gastrointestinal symptoms and endoscopy scores[1], gastrointestinal symptom scoring is defined as follows: 0 points, asymptomatic; 1 point, does not affect daily life; 2 points, mildly affects daily life; 3 points, moderately affects daily life; 4 points, severely affects daily life. Endoscopy scoring is defined as follows: 0 points, mucosal healing; 1 point, maximum ulcer ≤ original 1/4; 2 points, maximum ulcer between original 1/4 and 1/2; 3 points, maximum ulcer ≥ original 1/2 or enlargement. Marked improvement is defined as gastrointestinal symptom and endoscopy scores both ≤ 1. [1]Sugimura, N. et al. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease. Dig. Liver Dis. 51, 967-971 (2019). |
Baseline to week 24
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
与随访的第24周相比,胃肠道症状评分≥1点的患者比例
大体时间:基线到第24周
|
基线到第24周
|
|
|
Proportion of patients with CR (complete response) at week 24 of follow-up
大体时间:Baseline to week 24
|
CR is defined as both gastrointestinal symptoms and endoscopy scores being 0. |
Baseline to week 24
|
|
Changes in C-reactive protein (CRP) compared to baseline
大体时间:Baseline to week 24
|
The hs-CRP is acute phase reactants that are indicative of the patient's disease activity. |
Baseline to week 24
|
|
Changes in erythrocyte sedimentation rate (ESR) compared to baseline
大体时间:Baseline to week 24
|
The ESR is acute phase reactants that are indicative of the patient's disease activity. |
Baseline to week 24
|
|
Changes in DAIBD scores compared to baseline
大体时间:Baseline to week 24
|
Disease Activity Index for Intestinal Behcet's Disease (DAIBD); |
Baseline to week 24
|
|
Changes in BDCAF scores compared to baseline
大体时间:Baseline to week 24
|
Behçet's Disease Current Activity Index (BDCAF); |
Baseline to week 24
|
|
Changes in SF-36 of life questionnaires compared to baseline
大体时间:Baseline to week 24
|
Short Form (36) Health Survey(SF-36); |
Baseline to week 24
|
|
Changes in IBDQ quality of life questionnaires compared to baseline
大体时间:Baseline to week 24
|
Inflammatory Bowel Disease Questionnaire (IBDQ) |
Baseline to week 24
|
|
Incidence of Treatment-Emergent Adverse Events
大体时间:Baseline to week 24
|
Record the types, frequency, and severity of adverse events, as well as the number of study participants who were drop out due to any adverse events. Adverse event: Any medical condition that affects the health of the participant during the study or worsens a preexisting medical condition, regardless of whether it is causally related to the study, is considered an adverse event. This can be symptoms, signs, or abnormal laboratory tests. Serious adverse event (SAE): Any significant medical event that causes death, is life-threatening, requires hospitalization, results in permanent or severe disability or loss of function, or the investigator deems it a significant medical event that may seriously harm the participant or require medical intervention to prevent the above outcomes. The causal relationship between the serious adverse event and the study is determined by the investigator's discussion. |
Baseline to week 24
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- Baricitinib-IBS-PUMCH
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.